Foresight Diagnostics
Foresight Diagnostics is a CLIA-certified, CAP-accredited cancer diagnostics company founded in 2020 in Boulder, Colorado by Stanford physicians and scientists, and since February 2026 a wholly owned subsidiary of Natera. Its Foresight CLARITY minimal residual disease (MRD) platform is a liquid-biopsy test powered by proprietary PhasED-Seq phased-variant sequencing and bioinformatics, detecting circulating tumor DNA at an analytical sensitivity below one part per million across lymphoma, lung and other solid tumors. The company sells laboratory testing services to biopharma sponsors, academic researchers and clinicians rather than software: it operates a central laboratory and publishes no public developer program, API, SDK or machine-readable specification of any kind.
Foresight Diagnostics is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Diagnostics, Oncology, and Genomics.
Foresight Diagnostics’ developer surface includes product news, support, and 12 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Foresight Diagnostics Rate Limits
RATE LIMITSSecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Design & Contract 1
Pagination, idempotency, versioning, errors, and events
Access & Security 2
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Other 3
Properties that don't map to a standard resource type